ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1253

Evaluation of a Pre-Assessment Tool to Define the Spectrum of Autoimmune Diseases in an Underserved Environment

Gary Craig1, Keith Knapp2, Karen Ferguson1, Ruben Tavares3, Mary Bell4 and Sergio Schwartzman5, 1Discus Analytics LLC., Spokane, WA, 2Arthritis Northwest PLLC., Spokane, WA, 3Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Rheumatology, Hospital for Special Surgery, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: classification criteria, inflammatory arthritis and primary care, Referrals, Triage

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Healthcare Disparities in Rheumatology - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: American rheumatology practice patterns vary considerably. One challenge is practitioner shortage, thus a patient-self-administered screening tool would fill an unmet need if it identified patients with the highest likelihood of having an inflammatory disease (ID).

Objective: To assess the appropriateness of referral patterns and concurrently to evaluate a previously published screening tool, Early Inflammatory Arthritis-3 (EIA–3)1.

Methods: The US rheumatology database, JointMan® captures inflammatory/non-inflammatory diagnoses of referred patients at a large Washington State rheumatology practice. All patients at the practice fill in an electronic version of the EIA-3 tool. This published screening questionnaire estimates the likelihood of having an inflammatory disease [JIA, RA–fulfilling ACR criteria, Unspecified inflammatory arthritis, SpA, CTDs, SLE] vs non-inflammatory disease [OA, FM, CPPD]. The evaluating clinician was not aware of the EIA-3 results. The results were later correlated to the clinician’s diagnosis. Based on the confusion matrix, effect sizes (sensitivity, specificity and likelihood ratios) were calculated and compared to published results2.

Results: There were 956 patients with a mean age of 55; 66.32% female; 77.82% Caucasian. Of those,726 patients had inflammatory diseases [137 also had non-inflammatory disease]; 230 had non-autoimmune disease. The EIA-3 suggested referrals for 725 patients and no referral for 231.

Conclusion: In this study, primary care physicians adeptly referred appropriate ID patients to less accessible rheumatologists (EIA-3 use only modestly increased preselection of ID patients).  It is possible that an electronic patient generated screening tool may help primary providers referring ID patients in less preselected populations (as in the first EIA-3 trial where non-inflammatory diseases were more common).

1.       Bell et al. BMC MSK Disorders 2010, 11:50

2.       Tavares, R. et al. J. Rheumatol 40(4):417-424


Disclosure: G. Craig, Discus Analytics LLC., 4,Celgene, 8,UCB, 8,Genentech and Biogen IDEC Inc., 8,Novartis Pharmaceutical Corporation, 8,Bristol-Myers Squibb, 8,Novartis Pharmaceutical Corporation, 5,Bristol-Myers Squibb, 5; K. Knapp, Discus Analytics, 1,Discus Analytics, 3; K. Ferguson, Genentech and Biogen IDEC Inc., 8,Discus Analytics LLC., 4; R. Tavares, None; M. Bell, Paid Consultant of Janssen Inc., Canada, 5; S. Schwartzman, Genentech and Biogen IDEC Inc., 8,Genentech and Biogen IDEC Inc., 5,Abbott Immunology Pharmaceuticals, 5,Abbott Immunology Pharmaceuticals, 8,Janssen Pharmaceutica Product, L.P., 8,Janssen Pharmaceutica Product, L.P., 5,Pfizer Inc, 5,Pfizer Inc, 8,UCB, 5,UCB, 8,Regeneron, 5,Novartis Pharmaceutical Corporation, 8,Novartis Pharmaceutical Corporation, 5.

To cite this abstract in AMA style:

Craig G, Knapp K, Ferguson K, Tavares R, Bell M, Schwartzman S. Evaluation of a Pre-Assessment Tool to Define the Spectrum of Autoimmune Diseases in an Underserved Environment [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-a-pre-assessment-tool-to-define-the-spectrum-of-autoimmune-diseases-in-an-underserved-environment/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-a-pre-assessment-tool-to-define-the-spectrum-of-autoimmune-diseases-in-an-underserved-environment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.